Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Jul;14(1):97–98. doi: 10.1111/j.1365-2125.1982.tb04940.x

Cigarette smoking does not attenuate the cardiovascular effects of epoprostenol (prostacyclin) in humans

S Hassan, I C Macdougall, J O'Grady, Hilary Pickles
PMCID: PMC1427569  PMID: 7049210

Abstract

Infusion of epoprostenol (prostacyclin, PGI2) in human subjects leads to a rise in pulse rate, a fall in diastolic pressure and a rise in pulse pressure. In three healthy subjects these responses to PGI2 were identical before and after 30 min continuous cigarette smoking, and demonstrate that the attenuation of the PGI2 response by smoking reported in rats does not occur in healthy humans.

Full text

PDF
97

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boura A. L., Hui S. C., Walters W. A. Cigarette smoke inhalation specifically inhibits depressor responses to prostacyclin in the rat. Br J Pharmacol. 1981 May;73(1):3–5. doi: 10.1111/j.1476-5381.1981.tb16762.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Warrington S. J., Smith P. R., O'Grady J. Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man. Eur J Cardiol. 1980;12(2):73–80. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES